Skip to content
PRESS RELEASE

iPrescribe Passes Major Milestone With 6 Million Digital Prescriptions in 2021

Second Consecutive Year of 100% Growth for DrFirst’s Top-Rated E-Prescribing App: Essential Tool for Medical Professionals During the Pandemic 

Rockville, MD – Feb. 15, 2022 – Healthcare technology pioneer DrFirst today announced that the number of prescriptions written using its award-winning iPrescribe mobile app doubled for the second year in a row. 

A winner of multiple awards for innovative technology, iPrescribe continues to grow steadily. In 2021, nearly 6.5 million prescriptions were processed through iPrescribe, representing more than 100% growth year-over-year. Its user base grew to more than 26,000 prescribers, an 80% jump over the previous year. 

“With the upheaval and disruptions caused by the pandemic, healthcare providers need mobile options to help them care for their patients when they may not be face-to-face and when providers are on call or away from their office,” said Colin Banas, M.D., DrFirst’s chief medical officer. “iPrescribe provides critical safety features, such as alerts for potential drug interactions and allergies, and can be used for all prescriptions, including controlled substances, which are required to be electronically prescribed in many states. This means no more phone calls or faxes to pharmacies, which can take longer to process and also increase the risk of errors.” 

The E-Prescribing Solution That Goes Where You Go 

iPrescribe makes it easier for doctors to e-prescribe anytime and anywhere, even for controlled substances, with just a few taps on a phone. iPrescribe enables: 

  • Safer prescribing with access to DrFirst’s MedHx, bringing the most robust patient medication history available to prescribers’ fingertips 
  • Faster prescribing with artificial intelligence that cuts prescribing time down to seconds and with automatic patient record creation through DrFirst’s network of millions of patient-prescriber relationships 
  • More secure prescribing through seamless compliance with state and federal mandates around e-prescribing for controlled substances (EPCS) and in-app checking of prescription drug monitoring programs (PDMP) to help address the opioid crisis  
  • Visibility into patients’ out-of-pocket expenses and lower-cost alternatives through myBenefitCheck by DrFirst to help increase medication adherence 

iPrescribe can be used with or without an electronic health record (EHR) or electronic medical record (EMR), and nearly two-thirds of users (60%) report that it serves as a complement to these systems. “One of the common myths around e-prescribing is that a clinician can only use one system,” said G. Cameron Deemer, president of DrFirst. “As a result of that belief, far too many prescriptions are still called in to the pharmacy, disrupting workflow and bypassing all the safety and information advantages of e-prescribing. We designed iPrescribe to be everyone’s second system, to get doctors and pharmacists off the phone and free to spend more time with their patients and their families.” 

Prescribers can sign up and start using iPrescribe in minutes from their iPhone or Android phone. 

 

About DrFirst

Since 2000, DrFirst has pioneered healthcare technology solutions and consulting services that securely connect people at touchpoints of care to improve patient outcomes. We create unconventional solutions that solve care collaboration, medication management, price transparency, and adherence challenges faced in healthcare. We unite the Healthiverse—the interconnected healthcare universe—by providing our clients with real-time access to the information they need, exactly when and how they need it, so patients get the best care possible. DrFirst solutions are used by nearly 325,000 healthcare professionals, including more than 120,000 prescribers, 70,000 pharmacies, 280 HIS/EHRs, and 1,500 hospitals in the U.S. and Canada. To learn more, visit www.DrFirst.com and follow @DrFirst. 

 

# # # 

 

Contact: 

Alessandra Nagy 

alessandra@bospar.com 

 

 

 

What To Read Next